Resource Centre

We are a leading provider of 14C-enabled drug development programs, successfully conducting over 350 human ADME and other radiolabeled programs to date. Learn about Synthesis-to-Clinic®.

The use of electrospraying as a means of drug loading into mesoporous silica particles for enhanced dissolution, presented at the 13th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical (PBP) Technology 2022

Learn about drug substance and formulation considerations for improving downstream clinical outcomes. Access on demand.

Understanding the Absorption, Metabolism and Excretion of Masitinib in Healthy Male Subjects.

Safety, tolerability, and pharmacokinetics of the oligomer modulator anle138b: a first-in-human randomised, double-blind, placebo-controlled Phase 1 trial

A Decade of Human ADME at Quotient Sciences: Reviewing Key Study Design Variables and Outcomes.

Practical and operational considerations related to paediatric oral drug formulation: An industry survey.

A Phase I Study of the Cancer-specific Vaccine FMPV-1 in Healthy Male Subjects to Assess Safety and Immune Response

Development of a novel oral suspension formulation of a candidate API for administration to pediatric patients.

Qualification of Gastroplus® PBPK modelling software to support decision-making in clinical development.

Controlled synthesis of SPION@SiO2 nanoparticles using design of experiments.

Benznidazole pharmacokinetics in adults and children: Application of PBPK modelling.